| P2093 | author name string | Raj D Sheth | |
| | Georgia Montouris | |
| P2860 | cites work | Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy | Q31844365 |
| | Guidelines for healthy weight | Q33702693 |
| | A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group | Q33732579 |
| | Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy | Q79742881 |
| | Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital | Q82901006 |
| | Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes | Q82901030 |
| | Stable weight during lamotrigine therapy: a review of 32 studies | Q33848193 |
| | Oxcarbazepine in the treatment of epilepsy | Q34445634 |
| | The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. | Q34560736 |
| | Obesity as a disease: etiology, treatment, and management considerations for the obese patient | Q35029792 |
| | Classification of obesity and assessment of obesity-related health risks | Q35029800 |
| | Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy | Q35201012 |
| | Psychiatric comorbidity, health, and function in epilepsy | Q35599889 |
| | Obesity and pharmacologic therapy | Q35623051 |
| | The metabolic syndrome: an emerging risk state for cardiovascular disease | Q35824621 |
| | Endocrine and metabolic changes in epileptic patients receiving valproic acid | Q36142002 |
| | Seizures in medically complex patients | Q41548060 |
| | Transient renal tubular acidosis in a neonate following transplacental acetazolamide | Q43627412 |
| | Insulin-related metabolic changes during treatment with valproate in patients with epilepsy | Q43799181 |
| | Topiramate and metabolic acidosis in infants and toddlers | Q44053298 |
| | Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis | Q44078749 |
| | Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet | Q44169569 |
| | Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy | Q44172530 |
| | Predictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy | Q44400054 |
| | Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials | Q44672091 |
| | Gabapentin-induced hypoglycemia in a long-term peritoneal dialysis patient | Q44679658 |
| | Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures | Q44704337 |
| | Topiramate-induced renal tubular acidosis | Q44768175 |
| | The disease burden associated with overweight and obesity | Q44817527 |
| | Valproate therapy and nonalcoholic fatty liver disease | Q44880224 |
| | Serum lipid levels during carbamazepine therapy in epileptic children | Q45264505 |
| | A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group | Q45336272 |
| | Psychogenic nonepileptic seizures are associated with an increased risk of obesity | Q46776702 |
| | Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid | Q46848039 |
| | Valproate-induced insulin resistance in prepubertal girls with epilepsy | Q46851945 |
| | Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate | Q46897650 |
| | Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets | Q46983604 |
| | Weight gain during treatment with valproate | Q47236694 |
| | Risk of excessive weight gain in epileptic children treated with valproate | Q47259111 |
| | Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. | Q47303997 |
| | Changes in body weight with chronic, high-dose gabapentin therapy | Q47304187 |
| | The metabolic syndrome mediates the relationship between cynical hostility and cardiovascular disease. | Q50998321 |
| | Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. | Q51570720 |
| | Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. | Q52016801 |
| | Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. | Q53910273 |
| | Phenytoin-induced insulin insensitivity. | Q54283288 |
| | Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs | Q67553968 |
| | Serum lipid levels during carbamazepine medication. A prospective study | Q72220855 |
| | Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy | Q72319656 |
| | Felbamate | Q73210496 |
| | Renal tubular acidosis associated with zonisamide therapy | Q73291433 |
| | Efficacy of the ketogenic diet in focal versus generalized seizures | Q74595558 |
| | Complications of the ketogenic diet | Q74791636 |
| P921 | main subject | glucose | Q37525 |
| | lipid | Q11367 |
| P304 | page(s) | 329-346 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | International Review of Neurobiology | Q15754273 |
| P1476 | title | Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism | |
| P478 | volume | 83 | |